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Background: In Plasmodium, the high level of genetic diversity and the interactions established by co-infecting
parasite populations within the same host may be a source of selection on pathogen virulence and drug resistance.
As different patterns have already been described in humans and mosquitoes, parasite diversity and population
structure should be studied in both hosts to properly assess their effects on infection and transmission dynamics.
This study aimed to characterize the circulating populations of Plasmodium spp and Plasmodium falciparum from a
combined set of human blood and mosquito samples gathered in mainland Equatorial Guinea. Further, the origin and
evolution of anti-malarial resistance in this area, where malaria remains a major public health problem were traced.
Methods: Plasmodium species infecting humans and mosquitoes were identified by nested-PCR of chelex-extracted
DNA from dried blood spot samples and mosquitoes. Analysis of Pfmsp2 gene, anti-malarial-resistance associated
genes, Pfdhps, Pfdhfr, Pfcrt and Pfmdr1, neutral microsatellites (STR) loci and Pfdhfr and Pfdhps flanking STR was
undertaken to evaluate P. falciparum diversity.
Results: Prevalence of infection remains high in mainland Equatorial Guinea. No differences in parasite formula or
significant genetic differentiation were seen in the parasite populations in both human and mosquito samples. Point
mutations in all genes associated with anti-malarial resistance were highly prevalent. A high prevalence was observed
for the Pfdhfr triple mutant in particular, associated with pyrimethamine resistance.
Analysis of Pfdhps and Pfdhfr flanking STR revealed a decrease in the genetic diversity. This finding along with multiple
independent introductions of Pfdhps mutant haplotypes suggest a soft selective sweep and an increased differentiation
at Pfdhfr flanking microsatellites hints a model of positive directional selection for this gene.
Conclusions: Chloroquine is no longer recommended for malaria treatment in Equatorial Guinea but sulphadoxine-
pyrimethamine (SP) remains in use in combination with artesunate and is the only drug recommended in preventive
chemotherapy in pregnancy. The high prevalence of point mutations in Pfdhfr and Pfdhps points to the danger of an
eventual reduction in the efficacy of SP combined therapy in P. falciparum populations in Equatorial Guinea and to the
essential continuous monitoring of these two genes.
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Malaria continues to be one of the main public health
problems in the world, affecting 106 countries, with ap-
proximately 216 million cases resulting in 650,000 yearly
deaths [1]. This parasitic disease involves three living
entities with complex interactions among them and trans-
mission of Plasmodium parasites by their anopheline vec-
tors is a crucial factor determining the epidemiology of
malaria in endemic areas.
The level of genetic diversity of natural populations
of Plasmodium is well demonstrated and both inter-
and intra-specific mixed infections in the same host are
common, especially in highly endemic areas [2]. The
ecological interactions that these different and co-infecting
parasite populations establish among them may be a
source of selection on pathogen traits such as virulence
and drug resistance.
Parasite genetic diversity and population structure in
both humans and mosquitoes should be assessed in order
to better determine the influence of different parasite
populations on infection and transmission dynamics. In
fact, both different associations of Plasmodium species
as well as marked differences in the multiplicity of infec-
tion and allele diversity of Plasmodium falciparum pop-
ulations were previously reported [3]. Furthermore, a
recent analysis of both human peripheral blood samples
and mosquitoes from the same location has revealed a
completely unexpected picture related to the presence
of Plasmodium vivax in an area where it had not yet
been reported [4]. Differences have also been found in
drug-resistant associated genes. In Gabon, Mharakurwa
et al [5] reported that parasites in humans presented
high levels of pyrimethamine (PYR)-resistant mutants,
whereas parasites in Anopheles mosquitoes showed high
levels of cycloguanil-resistant mutants.
For a period of time, the genetic diversity of P. falciparum
populations has mainly been investigated through the
analysis of mutation in polymorphic surface antigen coding
genes [6,7]. However, this approach poses some limitations
as it is impossible to know whether observed patterns
reflect population history or natural selection [8]. Micro-
satellite sequences (STR), spread throughout the genome,
are currently the neutral markers most commonly used
to differentiate P. falciparum populations as these markers
(short repeated nucleotide sequences) often present high
levels of inter- and intra-specific polymorphism, particu-
larly when the number of repetition is 10 or higher.
In Equatorial Guinea, malaria remains the major en-
demic disease and the leading cause of child mortality
and morbidity. In recent years, the prevalence of infec-
tion has been reduced significantly on the Insular Region
due to an effective vector control [1,9] whilst the preva-
lence of infection remains above 50% in children under
five years old in mainland region [10]. Along with the highprevalence of infection, the dissemination of P. falciparum
drug resistance still remains the main constraint to control
malaria transmission in most endemic areas. Anti-malarial
resistance has largely been studied through the analysis
of mutations on several target genes associated with
resistance to specific drugs, e g, Pfcrt [11] and Pfmdr1
[12] linked to chloroquine (CQ) resistance; and Pfdhfr
[13] and Pfdhps genes [14] associated with resistance to
pyrimethamine (PYR) and sulphadoxine (SFX), respectively.
Increasing failure rates (40-50%) for CQ and around
25% resistance to sulphadoxine/pyrimethamine (SP) in
under-five children was reported in 2003 in Malabo, the
capital city of Equatorial Guinea located in the island of
Bioko [15]. Nevertheless, CQ continued to be used in
mainland region as the first-line treatment for uncom-
plicated malaria until 2009, and had been replaced by
artesunate + sulphadoxine/pyrimethamine (AS+SP) com-
bination on the island of Bioko in 2004 [16]. In 2009,
artemisinin combination therapy (ACT) of artesunate/
amodiaquine (AS/AQ) was adopted as first-line therapy
based on the high levels of resistance to SP in neighbouring
countries. More recently, a study conducted in Bata, the
largest city in the mainland region, and Malabo revealed
that AS/SP and AQ/SP combinations were both highly
effective for the treatment of uncomplicated P. falciparum
malaria [16]. SP is still prescribed alone for intermittent
preventive therapy in pregnant women [17].
This study aimed to characterize the circulating popu-
lations of Plasmodium spp and P. falciparum from a
combined set of human blood and mosquito samples
collected in both coastal and inland villages from main-
land Equatorial Guinea. Plasmodium falciparum diver-
sity was analysed through the study of an antigen coding
gene (Pfmsp2) as well as a set of neutral STR loci and
four anti-malarial resistant associated genes (Pfcrt, Pfmdr1,
Pfdhfr and Pfdhps). Finally, to trace the origin of anti-
malarial resistance and its progression in this area, the
presence of signatures of drug resistant selection in
P. falciparum populations were investigated. The impact
of these findings on control policies, especially the avoid-
ance of dissemination of P. falciparum drug-resistant par-
asites in Equatorial Guinea, is discussed.
Methods
Sample collection
Peripheral blood samples from 97 inhabitants (zero to
78 years-old) were collected in 2005 in mainland Equatorial
Guinea during the dry (February and August) and rainy
(May) seasons from two villages, Miyobo (34 and 43
individuals in the dry and rainy seasons, respectively;
44 different individuals in total) and Ngonamanga (40 and
26 individuals in the dry and rainy seasons, respectively;
53 different individuals in total). Blood sampling has
been performed in four consecutive days per individual,
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population’s composition. Further, 819 mosquito speci-
mens were also collected during the same period and
locations. Miyobo is located in a forested area on the
riverbank of the Wele River, which crosses the main-
land region from east to west. Ngonamanga is a coastal
village surrounded by forest-savannah, 60 km north of
Bata. In both, malaria is classified as hyperendemic. Both
study areas and sample collection procedures have been
described elsewhere [4].
Villagers were informed of the nature and aims of the
study and voluntary participation of five households ran-
domly selected by location was requested after approval
of local authorities. Blood samples were collected after
informed consent was received from all donors (parents
or guardians responded on behalf of children). Mosquito
collection was done after the approval of local author-
ities, the owner and occupants of the house. Written
consent was obtained from the legal guardians of the
recruited children and non-documented, oral consent was
only requested from adults, due to the community-wide
mistrust of signing official forms. The study was approved
by the Ethical Committee of Equatorial Guinea’s Ministry
of Health and Social Welfare, the National Malaria
Control Programme, and local health authorities from
the villages, which accepted the constraint and found
no bio-ethical impediments to the study. Ethical clear-
ance was also given by the Ethical Committees of the
Instituto de Higiene e Medicina Tropical (Lisboa, Portugal)
and the Instituto de Salud Carlos III (Madrid, Spain),
according to EU regulations.
DNA extraction and molecular assays
Individual mosquitoes, dried on silica gel, and blood spot
samples were stored at room temperature until DNA
preparation. DNA was extracted using chelex according
to Plowe et al [18] from blood spots and to Arez et al
[19] from mosquitoes.
Detection of malaria infection and identification of
Plasmodium species was carried out by nested-PCR ampli-
fication of the ssrRNA genes [20]. Plasmodium falciparum
positive samples were further genotyped for:
a) Pfmsp2 gene by a nested-PCR as in Snounou et al [21];
b) Drug resistant associated genes by a nested PCR-RFLP
analysis of the presence/absence of mutations at
codons 75 and 76 of the Pfcrt gene, codons 86 and
1246 of the Pfmdr1 gene, codons 51, 59, 108 and 164
of the Pfdhfr gene and codons 436, 437, 540 and 581
of the Pfdhps gene [22],
c) Nine neutral microsatellite loci (STR) distributed
throughout the genome of P. falciparum: TAA42,
TAA81 (chromosome 5), TA1, TAA87, TAA109
(chromosome 6), ARA2 (chromosome 11), TA102,PfPK2 and Pfg377 (chromosome 12). Primer
sequences and PCR conditions are described in
Anderson et al [23] and Conway et al [24];
d) STRs flanking Pfdhfr and Pfdhps genes located
0.3 kb, 4.4 kb and 5.3 kb upstream of codon 108 of
Pfdhfr (chromosome 4) and 0.8 kb, 4.3 kb and 7.7 kb
downstream from codon 437 of Pfdhps
(chromosome 8). Primer sequences and PCR
conditions are described in Roper et al [25],
Ndiaye et al [26] and Salgueiro et al [27].
Southeast Asian P. falciparum K1 laboratory strain
was used as reference (at STRs flanking the Pfdhps
gene, the allelic composition of the K1 strain
matches that of the East African Pfdhps double
mutant A437G/K540E haplotype lineage SGE 1 [28]).
Amplified fragments were run in an automatic sequen-
cer (ABI 3730, Applied Biosystem) at Yale University,
DNA Analysis Facility on Science Hill. The software
GeneMarker (SoftGenetics) was used to measure allele
sizes. Samples that failed the amplification in any of the
loci or presented multiple STR peaks were excluded for
the haplotype definition [25]. A new haplotype was con-
sidered when there was one or more allelic changes
across all loci considered. For the remaining analyses, in
cases where multiple peaks were present, only the value
of the highest peak per locus was scored [8].Statistical analysis
Pearson χ2 test was used to compare prevalence of infec-
tion between collection sites, seasons and hosts. Whenever
Pearson χ2 test conditions were not satisfied, Fisher’s exact
test was used (SPSS v.12 statistical software). Pearson’s χ2
test was also used to assess possible associations between
Plasmodium species [29].
Prevalence of Pfmsp2 alleles and the minimum num-
ber of concurrent genotypes in the same isolate (multi-
plicity of infection (MOI): the largest number of alleles
found in each sample) were calculated for all comparison
groups; mosquitoes versus blood samples, Miyobo versus
Ngonamanga and rainy season versus dry season.
STR data was analysed with FSTAT v. 2.9.3.2 [30] to
obtain measures of genetic diversity [allelic richness Rs:
a measure of the number of alleles independent of sample
size, hence allowing to compare this quantity between dif-
ferent sample sizes; and expected heterozygosity He per
locus and sample: this use an unbiased estimator Hs,
which is calculated from individual allele frequencies and
range from zero (no heterozygosity) to nearly 1.0 (for a
system with a large number of equally frequent alleles)]
and genetic differentiation using the Fst estimator. Linkage
disequilibrium (LD) tests were performed with GENEPOP
v.3.4 [31].
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wild type (or sensitive) and mutant alleles, comparisons
were made between populations classified as “wild type”,
“single mutant” (Pfdhfr: 51 or 59 or 108 or 164; Pfdhps:
436 or 437 or 540 or 581), “double mutant” (Pfdhfr:
51:108 or 59:108 or 51:59 or 51:164; Pfdhps: 436:581 or
437:581 or 540:581), “triple mutant” (Pfdhfr: 51:59:108
or 59:108:164 or 51:59:164, Pfdhps: 436:437:581 or
436:540:581), “quadruple mutant” (Pfdhfr: 51:59:108:164,
Pfdhps 436:437:540:581). However this was not always
possible due to the low number of samples in some
groups, so that only the whole sample was subdivided and
compared according to geographic collection sites.
In multiple tests, Bonferroni correction was applied by
dividing 0.05 by the number of tests to minimize type I
errors and obtain the actual cut-off for significance [32].Results
Detection and identification of Plasmodium species
A total of 427 blood samples from 97 individuals were
collected in both villages and seasons (44 individuals
from Miyobo and 53 from Ngonamanga). A total of 819
mosquitoes were collected (509 from Miyobo and 310
from Ngonamanga), 536 belonging to Anopheles
gambiae complex, 259 belonging to Anopheles nili com-
plex (presumably Anopheles carnevalei), three to Anoph-
eles funestus complex and 21 Anopheles moucheti
moucheti.
In order to determine prevalence of infection, an indi-
vidual was defined as infected if he/she had at least one
positive sample among the multiple samples collected;
therefore, only one sample was considered per individual
and all calculations were performed having the number
of individuals as denominator. Overall, prevalence of
Plasmodium spp infection in humans was 93% in Miyobo
and 81% in Ngonamanga, and was higher in the dry
season (69%) than in the rainy (67%). In mosquitoes, the
prevalence of infection was slightly higher in Ngonamanga
(20%) than Miyobo (19%) and in the rainy season (22%)
than in the dry season (16%). Although the four Plasmo-
dium species were detected in both hosts, P. falciparum
was the predominant species occurring in 90% of the iso-
lates (both humans and mosquitoes) either in single or
mixed infection (see Additional files 1 and 2). In humans,
Plasmodium malariae was the second most prevalent
species, occurring in 13% of individuals, followed by
P. vivax (10%) and finally Plasmodium ovale (8%) (see
Additional file 1). In mosquitoes, P. vivax was the second
most prevalent species (9%), followed by P. malariae (4%)
and P. ovale (2%) (see Additional file 2). A significantly
higher number than expected of mixed infections with
P. falciparum and P. malariae in both hosts (blood sam-
ples: χ2=8.973, p=0.003; mosquitoes: χ2=15.745, p<0.001)was found. No association was found for the pair P. falcip-
arum and P. vivax.Plasmodium falciparum genetic diversity
Pfmsp2
Plasmodium falciparum was detected in 302 out of
the 427 samples collected and successful genotyping of
Pfmsp2 gene was achieved in 73% (221/302) P. falciparum-
positive blood samples and none in the 275 P. falciparum-
positive mosquitoes. The unsuccessful amplification of
Pfmsp2 in mosquitoes was probably due to degradation
of parasite DNA in dried mosquitoes stored at room
temperature for a long period of time.
No major differences in allelic diversity were detected
between seasons or villages, which shared 11 out of 13
alleles; two unique alleles were detected in Ngonamanga
in dry season (IC_400 and IC_700) and only one was
observed in the rainy season (FC27_250) in both vil-
lages. The mean MOI was slightly higher in Miyobo
than in Ngonamanga; 1.98 versus 1.83, respectively, and
varied between 1.46 (Ngonamanga, rainy season) and 2.19
(Ngonamanga, dry season). When values are compared
between villages without season distinction, mean MOI
was slightly higher in Miyobo than in Ngonamanga (1.98
versus 1.83, respectively) and it was higher in the dry sea-
son in Ngonamanga (dry versus rainy: 2.19 versus 1.46),
while the opposite occurred in Miyobo (dry versus rainy:
1.88 versus 2.07).Neutral STRs loci
Ninety-nine per cent (299/302) P. falciparum-positive
blood samples and 83% (228/275) P. falciparum-positive
mosquitoes were successfully genotyped. The number of
observed alleles (Na), allelic richness (Rs) and genetic di-
versity (uH) are shown in Table 1. All nine STR analysed
were polymorphic and the number of alleles varied be-
tween seven in Pfg377 and 17 in TA109 in human sam-
ples, and six in TA42 and 18 in TA109 in mosquitoes. The
majority of samples presented multiple P. falciparum ge-
notypes but in general, the most common alleles are
shared between parasite populations present in humans
and mosquitoes. Genetic diversity (uH) also presented
similar values; 0.75 versus 0.77, in humans and mosqui-
toes, respectively, as well as the number of alleles for each
locus; 12 versus 11, in humans and mosquitoes respectively
(see Table 1).
MOI varied between 1.62 (Miyobo, dry season, mos-
quitoes) and 2.25 (Ngonamanga, dry season, humans)
and tended to be higher in humans than in mosquitoes
(2.09 versus 1.80, respectively). When values are com-
pared between villages without season distinction, mean
MOI in humans was slightly higher in Ngonamanga (2.07)
than in Miyobo (2.11), and conversely in mosquitoes;
Table 1 Neutral microsatellite diversity of Plasmodium falciparum populations from Ngonamanga and Miyobo in
humans and mosquitoes
n TA1 TA102 ARA2 TA87 Pfk2 TA81 TA42 Pfg377 TA109 Mean
Humans TBs 299 Na 13 12 9 15 14 11 14 7 17 12
Rs 12 11 8 12 13 10 10 5 13 10
uH 0.852 0.832 0.787 0.838 0.877 0.829 0.344 0.612 0.799 0.75
BsM 195 Na 11 11 9 14 12 11 7 7 15 11
Rs 10 9 8 9 10 9 5 5 9 8
uH 0.846 0.848 0.771 0.829 0.857 0.792 0.293 0.642 0.811 0.74
BsN 104 Na 11 8 8 9 11 10 11 5 9 9
Rs 10 7 8 8 11 10 7 5 7 8
uH 0.859 0.771 0.809 0.844 0.877 0.868 0.424 0.531 0.747 0.75
BsW 141 Na 10 11 7 13 12 11 8 5 9 10
Rs 9 10 7 10 11 10 6 5 8 8
uH 0.819 0.854 0.797 0.840 0.874 0.851 0.307 0.634 0.805 0.753
BsD 158 Na 11 10 9 11 12 10 11 7 13 10
Rs 10 8 8 9 11 9 8 5 9 9
uH 0.866 0.817 0.766 0.841 0.871 0.798 0.375 0.592 0.788 0.746
Mosquitoes TMq 228 Na 13 12 8 11 12 10 6 8 18 11
Rs 12 12 8 11 12 10 6 7 16 10
uH 0.88 0.874 0.810 0.849 0.833 0.779 0.365 0.712 0.869 0.77
MqM 130 Na 12 11 7 9 12 9 6 6 15 10
Rs 10 11 7 8 10 8 6 5 13 9
uH 0.851 0.870 0.780 0.845 0.845 0.753 0.462 0.713 0.848 0.77
MqN 98 Na 9 7 7 8 8 8 3 6 14 8
Rs 9 7 7 8 8 8 3 6 11 7
uH 0.862 0.815 0.760 0.814 0.816 0.747 0.191 0.718 0.837 0.73
MqW 86 Na 11 11 5 9 12 9 6 7 8 9
Rs 10 11 5 9 11 9 6 6 8 8
uH 0.882 0.904 0.741 0.823 0.846 0.774 0.428 0.717 0.808 0.769
MqD 142 Na 10 7 8 9 10 8 4 5 17 9
Rs 10 7 8 9 10 8 4 5 14 8
uH 0.873 0.796 0.834 0.826 0.825 0.788 0.300 0.713 0.873 0.758
n: sample size; TBs: total of blood samples; BsM: Blood samples from Miyobo; BsN: Blood samples from Ngonamanga; BsW: Blood samples wet season; BsD:
Blood samples dry season; TMq: total mosquitoes; MqM: Mosquitoes from Miyobo; MqN: Mosquitoes from Ngonamanga; MqW: Mosquitoes wet season; MqD:
Mosquitoes dry season; Na: number of observed alleles; Rs: allelic richness; uH: unbiased estimation of genetic diversity.
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significant genetic differentiation was observed among all
study groups.
Drug resistant associated genes
SNPs: Pfcrt, Pfmdr1, Pfdhfr and Pfdhps
No major differences in the prevalence of mutant alleles
were found among villages or seasons for any of the
genes. Regarding Pfcrt and Pfmdr1 genes associated with
CQ resistance, the prevalence of the Pfcrt mutant alleles
(N75E and K76T), present in single or mixed infection,
was 56% and 72% in humans and 64% and 54% inmosquitoes; and a much higher prevalence of mutation
in codon N86Y (84% and 61%, in humans and mosqui-
toes, respectively) than in D1246Y (1% in both hosts)
was found in Pfmdr1 gene (see Additional file 3). Re-
garding Pfdhfr gene, mutations N51I, C59R and S108N,
associated with PYR resistance, presented prevalence,
when in single or mixed infection, of 73%, 85%, 93% in
humans and 81%, 81%, 95% in mosquitoes, respectively.
The codon I164L was found in very low frequency (15%
in humans and 0 in mosquitoes) (see Figure 1 and
Additional file 3). While in Miyobo the double mutation
(C59R/S108N) was the most prevalent in Ngonamanga
a
b
Figure 1 Total prevalence of mutations in the eight codons of Pfdhfr and Pfdhps genes. Legend: Prevalence of mutations in the Pfdhfr
(N51I, C59R, S108N, I164L) and Pfdhps (S436A, A437G, K540, 581G), in single (wild type or mutant) and mixed infections in both seasons and
localities in humans (a) and mosquitoes (b).
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S108N).
Mutations A437G and A581G in Pfdhps gene associ-
ated with SFX resistance were detected at very high
prevalence, the latter reaching 100%, whereas a very low
prevalence of codon K540E was found (1% in humans
and 6% in mosquitoes only in mixed infections)
(see Figure 1 and Additional file 3). Mutation S436A
occurred in 38% in humans and 14% in mosquitoes.
When comparing the two villages, no major differences
were found in mosquitoes, and the prevalence of mutant
alleles were: 12% in Ngonamanga and 20% in Miyobo,
unlike in humans where the prevalence of this mutation
was higher in Ngonamanga (51%) than in Miyobo
(31%).Most samples presented the double mutation (A437G/
A581G), but many samples (approximately 38%) containing
the triple mutation (A436/G437/G581) were identified
in Ngonamanga.
Despite the high prevalence of resistance-associated mu-
tations in Pfdhfr and Pfdhps, no parasites containing the
quintuple mutation (N51I/C59R/S108N/A437G/K540E)
associated with the clinical failure of SP combination
were found.
STR loci flanking Pfdhfr and Pfdhps genes
The analysis using the STR flanking Pfdhfr and Pfdhps
genes was only conducted in human isolates, since the
amplification rate of these loci was very low in mosquito
samples.
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The effect of SP selection on the P. falciparum popula-
tion of Equatorial Guinea was evaluated by examining
and comparing the levels of genetic diversity, LD and
genetic differentiation between the Pfdhfr and Pfdhps
flanking and neutral STR loci. Overall, genetic diversity
estimated at neutral loci (He = 0.75; Rs = 14; N =244)
was higher than at loci flanking both Pfdhfr (He = 0.15;
Rs = 8; N =189) and Pfdhps (He = 0.80; Rs = 12; N = 189)
genes (see Tables 2 and 3). In parasites holding Pfdhfr re-
sistance associated alleles, triple mutants showed lower
levels of genetic diversity (0.11) when compared to the
single (0.36) and double mutants (0.21) (see Table 2).
The mean He at three Pfdhfr loci was 0.22, which was
much lower when compared to the mean He at 9 neu-
tral loci (0.74) (see Table 2).
The reduction in the genetic diversity is not so marked
in Pfdhps as in Pfdhfr. When double mutants and triple
mutants are compared, there is a slight decrease in gen-
etic diversity (He=0.81 for double versus He=0.67 for
triple mutants) but values are still similar and high (see
Table 3). Statistical tests for LD were conducted for all
pairs of flanking STR on each of the mutant groups –
single, double and triple mutants (105 possible tests for
Pfdhfr and 316 for Pfdhps). Only two associations showed
significant results (p <0.05), after Bonferroni’s correction
was applied, in the Pfdhps double mutants group, involv-
ing loci 0.8 kb/4.3 kb and 4.3 kb/7.7 kb. No significant
pairwise association was found involving the Pfdhfr gene.
Pfdhfr and Pfdhps haplotype characterization
Only samples with single infections and successful
amplification of all loci were used for the haplotype
characterization. Thus, haplotypes were reconstructed
in 57 out of 298 human isolates genotyped for Pfdhfr and
in 35 out of 296 human isolates genotyped for Pfdhps. For
the Pfdhfr gene, nine distinct haplotypes were found (see
Additional file 4). The haplotype H9, an exact match of
the P. falciparum K1 strain used as a control (double
mutation C59R/S108N and allele sizes of 113 bp, 183 bp
and 210 bp to the 0.3 kb, 4.4 kb and 5.3 kb loci, respect-
ively), was found in 10 samples from Miyobo. Most fre-
quent haplotypes in 53 out of 57 samples (H1, H3, H5,
H8) also matched STR sizes in K1 strain.
The majority of samples from Ngonamanga (97%) showed
the triple-mutant IRNI (51I:59R:108N:164I – mutated
codons appear underlined), while in Miyobo the most
prevalent haplotype was the double-mutant NRNI (51N:
59R:108N:164I) (43%) followed by the triple-mutant IRNI
with 26% (see Additional file 4).
Regarding the Pfdhps gene, 25 distinct haplotypes were
found (see Additional file 5); 16 in Miyobo and nine in
Ngonamanga, only one shared between the two villages.
None of the haplotypes found matches with K1 strain(single mutation A437G and allele sizes of 131 bp, 103 bp
and 108 bp to the 0.8 kb, 4.3 kb and 7.7 kb loci, respect-
ively). The haplotypes found for the Pfdhps gene have
multiple independent lineages since the majority of the
haplotypes were unique. Nevertheless, the most prevalent
haplotype in Ngonamanga was the triple-mutant AGKG
(436A:437G:540K:581G) with 38%, whilst in Miyobo it was
the double-mutant SGKG (436S:437G:540 K:581G) (63%).
Discussion
Malaria still is a major public health concern in Equator-
ial Guinea, especially in the mainland. In order to con-
tribute to the update of the malaria situation in this
area, a combined set of blood and mosquito samples
from the same locations were analysed to characterize
the genetic diversity of circulating populations of Plas-
modium spp and especially of P. falciparum, in both
hosts.
Plasmodium species diversity
This study presents a much higher prevalence of Plasmo-
dium infection in mainland Equatorial Guinea (87%) than
the one reported for the Insular Region in 2005 (32%)
[33]. This difference is likely due to the fact that most mal-
aria control activities have been deployed on the island of
Bioko where the capital, Malabo is located. In 2004, the
first stage of the project “The Bioko Island Malaria Con-
trol Project (BIMCP)” was launched and initial reports
stated a significant decrease in the prevalence of infection,
achieving an overall malaria prevalence of 18% in 2008
[10,34]. In the present study, although P. falciparum infec-
tions were the most frequent, P. vivax infections were
detected for the first time both in humans and mosqui-
toes, which means that active transmission of this species
not previously reported in this area is occurring. The
apparent higher presence of P. vivax in mosquitoes
might be due to its higher visibility in the vector, since
in the human host this parasite can form dormant
forms in the liver – hypnozoites - and go unnoticed,
as discussed in [4].
Regarding mixed infections, P. falciparum and P. malariae
are also associated in mainland Equatorial Guinea, as has
been reported in other sub-Saharan countries [3,35-39].
This association was observed both in humans and
mosquitoes, which suggests that no differing patterns of
Plasmodium species association in the two hosts occurs
as has formerly been reported in Guinea Bissau [3].
Plasmodium falciparum genetic diversity
Concerning P. falciparum genetic diversity, the analysis
of both Pfmsp2 and neutral STR in humans showed
similar levels of allelic diversity and MOI in both villages
and seasons. No reduction of genotype diversity or MOI
was observed with the decline of transmission, as seen
able 2 Statistics of the 15 STR loci of Plasmodium falciparum-positive individuals: mutants to PYR
icrosatellites
Sampled populations - Miyobo Sampled populations - Ngonamanga
Single mutant Double mutant Triple mutant All samples Triple mutant
(N=10) (N=37) (N=17) (N=64) (N=82)
Rs He Rs He Rs He Rs He FST Rs He
oci flanking dhfr gene Dhfr 0.3 3 0.51 3 0.32 2 0.15 3 0.33 0.02 7 0.26
Dhfr 4.4 1 0.00 2 0.14 2 0.17 2 0.10 −0.04 3 0.10
Dhfr 5.3 3 0.56 2 0.18 1 0.00 2 0.24 0.10 3 3 0.08
All loci 2 0.36 2 0.21 2 0.11 2 0.22 0.03 5 4 0.15
eutral loci TA1 4 0.82 5 0.83 6 0.89 6 0.85 0.04 4 12 0.87
TA102 4 0.64 7 0.88 5 0.84 6 0.79 0.03 8 0.78
ARA2 4 0.69 5 0.77 6 0.79 5 0.75 −0.03 9 0.81
TA87 4 0.87 6 0.85 5 0.81 6 0.84 0.01 9 0.84
PfPK2 5 0.93 6 0.86 5 0.85 6 0.88 −0.03 12 0.87
TA81 4 0.87 5 0.81 4 0.71 5 0.80 −0.04 10 0.87
TA42 3 0.60 2 0.11 2 0.28 2 0.32 0.06 8 0.36
Pfg377 3 0.67 3 0.56 3 0.65 3 0.62 −0.04 7 0.55
TA109 5 0.86 5 0.80 4 0.79 5 0.82 0.04 3 8 0.75
All loci 4 0.77 5 0.72 4 0.73 5 0.74 <0.01 9 0.74
: number of isolates genotyped, He: expected heterozygosity; Rs: allelic richness. All loci: mean over loci Rs and He and global Fst over loci as calculated by FS T. P: P-values of permutation tests to assess





































able 3 Statistics of the 15 STR loci of Plasmodium falciparum-positive individuals: mutants to SFX
icrosatellites





All samples (N=60) Double mutant Trip mutant All samples (N=85)
(N=63) (N=2
(N=17) (N=43)
Rs He Rs He Rs He FST P Rs He Rs He Rs He FST P
oci flanking dhps gene Dhps 0.8 4 0.60 5 0.75 5 0.67 0.02 NS 9 0.81 5 0.64 9 0.73 0.06 0.01
Dhps 4.3 6 0.83 5 0.77 6 0.80 <0.01 NS 7 0.78 4 0.71 7 0.75 0.13 <0.01
Dhps 7.7 6 0.79 7 0.84 8 0.82 0.09 <0.01 10 0.85 6 0.67 10 0.76 0.14 <0.01
All loci 5 0.74 6 0.79 6 0.76 0.04 <0.01 9 0.81 5 0.67 9 0.74 0.11 <0.01
eutral loci TA1 5 0.79 8 0.87 8 0.83 0.04 NS 9 086 8 0.88 9 0.87 <0.01 NS
TA102 5 0.78 9 0.87 9 0.83 0.04 0.01 6 0.75 7 0.86 7 0.80 <-0.01 NS
ARA2 6 0.79 6 0.69 7 0.74 0.06 <0.01 7 0.80 6 0.82 7 0.81 −0.01 NS
TA87 5 0.79 8 0.84 7 0.82 0.05 0.02 8 0.83 7 0.87 8 0.85 0.02 NS
PfPK2 5 0.83 8 0.80 8 0.81 0.11 0.02 10 0.87 8 0.87 11 0.87 0.02 <0.05
TA81 5 0.77 6 0.78 7 0.78 −0.02 NS 9 0.88 8 0.83 9 0.85 <0.01 NS
TA42 1 0.00 4 0.29 3 0.14 0.03 NS 5 0.44 3 0.18 5 0.31 0.05 0.04
Pfg377 3 0.56 4 0.59 3 0.57 <-0.01 NS 5 0.59 3 0.40 5 0.50 0.01 NS
TA109 6 0.86 6 0.81 6 0.83 −0.02 NS 5 0.72 5 0.60 6 0.66 0.16 <0.01
All loci 5 0.69 6 0.73 6 0.71 0.03 <0.01 7 0.75 6 0.70 7 0.72 0.03 0.01
: number of isolates genotyped, He: expected heterozygosity; Rs: allelic richness. All loci: mean over loci Rs and He and global Fst over loci as calculated by FS T. P: P-values of permutation tests to assess
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http://www.malariajournal.com/content/12/1/114in areas of lower endemicity, such as Sudan [40] or in
areas with marked differences in malaria endemicity [41].
However, analogous results were obtained by Cano et al
[42] in a study conducted on the island of Annobon, part
of Equatorial Guinea Insular Region.
In mosquitoes, this analysis was only possible with
the neutral STR and the results confirmed those obtained
in humans, i. e., high levels of genetic diversity and no
significant genetic differentiation between geographic
locations, despite their different ecological differences
or seasons. This is a sign of high malaria endemicity in
mainland Equatorial Guinea and the similarity between
population genetic structures is concordant with other
studies in African highly malaria-endemic countries [8,40].
No significant genetic differentiation was seen between
hosts, when comparisons between human blood samples
and mosquitoes were made using neutral STR data. The
most common alleles are found in both humans and
mosquitoes, which may indicate consistency in the
parasite populations that are being transmitted. Never-
theless, MOI values were higher in humans than in
mosquitoes. As Arez et al [3] observed, a higher pro-
portion of single-genotype infections in mosquitoes could
point to a limited genetic diversity of the inocula and a
high genetic diversity in humans resulting from super-
infection phenomena.
Anti-malarial resistance evolution
The prevalence of the main point mutations associated
with CQ resistance (75E and 76 T of Pfcrt gene and 86Y
of Pfmdr1 gene) was nearly 71%. Although the mutation
1246Y in the Pfmdr1 gene has also been associated with
reduced susceptibility to CQ [43], a very low frequency
of this mutation was found in Equatorial Guinea (1%).
Nowadays, after the introduction of artemisinin-based
combination therapy (ACT), decrease in prevalence of
mutations associated with CQ resistance might be expected,
due to the absence of drug pressure, as reported in Malawi,
China, Kenya and Angola [44-47]. However, a recent study
conducted in Equatorial Guinea [48] found higher preva-
lence of mutation in Pfcrt (codon 76) and in Pfmdr1 (codon
1246) (98% and 96%, respectively), than those found in this
study (72% for Pfcrt codon 76 and 1% for Pfmdr1 codon
1246) in isolates collected in 2005, when CQ was still in use
in mainland Equatorial Guinea. The increasing of these
and other point mutants might be a result of selective
pressure by AS-AQ combination, since AQ is a close
Mannich base analogue of CQ, promoting the mainten-
ance of CQ-resistant isolates with the mutant Pfcrt and
Pfmdr1 genotypes. On the other hand, another possibil-
ity is the continuous use of CQ despite national thera-
peutic guidelines [49].
In Equatorial Guinea, SP has been used as a second-
line therapy for many years and lately, though lessintensely, as a first-line in combination with artemisi-
nin derivatives and it is used in preventive chemother-
apy in pregnancy. Although the failure rate of this
combination has not suffered major variations since
1992, and in the late 1990s was still 10% [15], it was
expected that the continuous use of this drug would
rapidly lead to an increase of resistance levels as had
happened in other countries such as Kenya [50] and
Tanzania [51].
In fact, a high prevalence of mutation in genes associ-
ated with resistance to the SP combination (~70%) was
observed in this study. PYR resistance seemed to be well
established in mainland Equatorial Guinea and nearly
80% of parasite populations presented the triple mutant
N51I/C59R/S108N in the Pfdhfr gene, both in humans
and mosquitoes, as seen in other nearby countries
such as Cameroon [52], Gabon [53] and São Tomé and
Principe [27].
Regarding SFX resistance, a high prevalence of the
mutation A437G in Pfdhps was detected. However the
mutation K540E was practically non-existent, which is
usual in West Africa [28]. The prevalence of S436A
mutation was low, contrary to data from the neighbouring
country Gabon, where this was the most frequent Pfdhps
polymorphism [54]. The mutations S436A and A581G are
less studied due to their low prevalence in some African
countries, and the lack of knowledge of their role in treat-
ment failure [55]. However, the prevalence of A581G
mutation in this study reached 100%. Other recent studies
conducted in different African countries showed an in-
crease of the prevalence of A581G, during the last
years [53,56].
The quintuple mutant, associated with SP clinical failure
[57,58] and resulting from the combination of the Pfdhfr
triple mutant N51I/C59R/S108N (linked to resistance
to PYR) with the Pfdhps double mutant A437G/K540E
(linked to resistance to SFX), was not detected since no
samples containing the latter were found. No major dif-
ferences in the prevalence of mutation between para-
sites in humans and mosquitoes occurred.
Analysis on Pfdhfr flanking STRs showed that the
majority of haplotypes found were associated with triple
mutants IRNI, especially in Ngonamanga, while the major-
ity of isolates harboured double mutants NRNI in Miyobo.
These two haplotypes have already been reported in
Ghana [59] and the triple mutant IRNI was also found in
Southeast Asia [60]. The majority of the haplotypes seems
to have a single origin. In fact, the haplotypes found were
very similar among them, with the majority of them corre-
sponding to the H3 haplotype. This haplotype has arisen
from H9 haplotype double mutant through an additional
mutation occurring at position 59 of the Pfdhfr gene.
Both H3 and H9 haplotypes share the same microsatel-
lite profile.
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sistance was firstly established in Ngonamanga, probably
due to the fact that Miyobo is more isolated and the
introduction of the drug may have occurred later. It is
likely that SP combination has been introduced first in
Malabo (the capital of the country), and then its
utilization was spread all over the country. Ngonamanga,
being a coastal area (closer to the capital), may have
started to use this drug earlier, and therefore to develop re-
sistance sooner. The process of the addition of a single mu-
tation in Pfdhfr alleles to double mutants, originating a
high prevalence of triple mutants [61] was still occur-
ring in Miyobo. The most common haplotype 113/183/
210 with the triple mutant IRNI, already described in
Senegal [26], should be related to the 109/183/210 back-
ground, found in Tanzania, South Africa, Southeast Af-
rica [25] and, most recently, in Kenya [50].
It was expected that the extensive use of SP would
lead to a rapid increase in resistance levels, leaving sig-
natures of drug selective pressure, such as a reduction in
genetic diversity around Pfdhps and Pfdhfr due to select-
ive sweep; an increased genetic differentiation at the
loci under selection; and, a significant LD between loci
flanking Pfdhps and Pfdhfr genes [62].
Indeed, the reduction in heterozigosity in the loci
flanking Pfdhfr gene with regard to the mean of
heterozigosity in the neutral loci indicates that this gene
has undergone strong selection in Equatorial Guinea.
The higher mean of He around double mutant than the
mean of He around triple mutant is consistent with a
model of positive directional selection. The Fst values at
STR loci linked to Pfdhfr gene were higher when com-
pared with mean Fst at neutral loci, which supports this
hypothesis. However, no significant LD values were
found between flanking genes of interest.
According to the results herein presented, SFX resistance
seems to have appeared more recently than PYR resistance
in mainland Equatorial Guinea. Indeed, only mutations at
codons A437G and A581G, from the Pfdhps polymorphic
sites surveyed showed high prevalence. Point mutations at
S436A and K540E codons were rarely seen. A wide diver-
sity of haplotypes was detected, being the majority unique
haplotypes, which is consistent with independent ori-
gins for those alleles. The most prevalent haplotype match
with AGK1/SGK1 lineages of West African origin and a
few others (436A:437G:540K/ 436S:437G:540 K) with prob-
able independent origin. The double mutant lineage identi-
fied as SGE1 (436S:437G:540E), originated in East Africa
[28], was not detected in this study. As occurred with PYR
resistance, the resistance to SFX seems to have been
established earlier in Ngonamanga, where the prevalence
of triple mutants is higher than in Miyobo.
When double mutants (He=0.81) were compared with
triple mutants (He=0.67), a reduction in the heterozigositywas seen. However the values found are remarkably higher
when comparing to those found for the PYR resistance
(mean He=0.22). These differences may be due to the
presence of multiple lineages occurring within individ-
ual populations. Also, significant LD values were found
between flanking Pfdhps gene, involving loci 0.8 kb/
4.3 kb and 4.3 kb/7.7Kb. Overall, these results might be
suggestive of soft selective sweep, where multiple line-
ages are superimposed within a single population caus-
ing higher He values than in populations where a single
lineage is present [63].
The results gathered in this study suggests that the
PYR resistance has been established for a while in main-
land Equatorial Guinea leaving selection signatures as
the decrease in genetic diversity and an increased
genetic differentiation at the loci around Pfdhfr gene.
In addition, the impact on genetic diversity was less
clear at the loci flanking Pfdhps, with only evidence
of a soft selective sweep effect. This agrees with a more re-
cent introduction of resistance to SFX in Equatorial Guinea,
which is in agreement with results obtained in a recent
study [64].
Conclusions
CQ is no longer recommended for malaria treatment in
Equatorial Guinea but SP remains in use in combination
with artesunate and is the only drug recommended for
intermittent preventive therapy in pregnancy [65]. Preva-
lence of infection in the mainland region, where most of
the country’s population live, remains high despite the
efforts undertaken to control malaria transmission mainly
on the island of Bioko [10,34]. A close and continuous
monitoring of point mutations frequency in the two genes
associated with SP resistance, Pfdhfr and Pfdhps, is essen-
tial since there is the danger of an eventual reduction in
the efficacy of SP combined therapy.
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